We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Pathogenesis of Superior Limbic Keratoconjunctivitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00167050
Recruitment Status : Unknown
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : September 14, 2005
Last Update Posted : November 28, 2005
Sponsor:
Information provided by:

Study Description
Brief Summary:
Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. This project will be conducted into through two parts: one is to investigate the presentation of chemokine receptors on mast cell and matrix metalloproteinases on fibroblasts by immunohistochemistry method from the pathological specimens of SLK patients who received conjunctiva resection as the treatment. The other part is to investigate the mRNA level of those chemokine receptors via reverse transcription - polymerase chain reaction from the conjunctiva collecting form SLK patients.

Condition or disease
Superior Limbic Keratoconjunctivitis

  Show Detailed Description

Study Design

Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Study Start Date : July 2005
Estimated Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Superior limbic keratoconjunctivitis patients who receive conjunctiva resection

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00167050


Contacts
Contact: Fung-Rong Hu, MD 886-2-23123456 ext 5189 fungrong@ha.mc.ntu.edu.tw
Contact: Yi-Chen Sun, MD 886-968195019 yichen.sun@msa.hinet.net

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Fung-Rong Hu, MD    886-2-23123456 ext 5189    fungrong@ha.mc.ntu.edu.tw   
Contact: Yi-Chen Sun, MD    886-968195019    yichen.sun@msa.hinet.net   
Principal Investigator: Fung-Rong Hu, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Fung-Rong Hu, MD National Taiwan University Hospital
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00167050     History of Changes
Other Study ID Numbers: 9461700634
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: November 28, 2005
Last Verified: June 2005

Additional relevant MeSH terms:
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases